This Week in Pediatric Oncology

This Week in Pediatric Oncology header image 1

Entries Tagged as 'cancer risk'

TWiPO #58 ~ Interview with Dr. Damon Reed

October 17th, 2016 · Comments

TWiPO Host Dr. Timothy Cripe, with co-hosts Dr. Nilay Shah and Dr. Bhuvana Setty welcome Dr. Damon Reed, Director of the Adolescent and Young Adult Program at Moffitt Cancer Center and Leader of the Pediatric Cancer Foundation's pediatric phase I consortium, the Sunshine Project. Dr. Reed shares his view points on how we can improve and accelerate the current trajectory with regard to pediatric therapy development. 


Tags: families · cancer risk · cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma · medulloblastoma · sarcoma · research · brain tumor · immunotherapy · clinical trials · Advancement in Cancer Research

TWiPO #53 ~ Interview with Linda McAllister-Lucas

April 13th, 2016 · Comments

On today's podcast TWiPO host Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-hosts, Dr. Nilay Shah (Nationwide Children’s Hospital) and Dr. Robyn Dennis (Nationwide Children’s Hospital) Interview Dr. Linda McAllister-Lucas (Chief of Service, Hematology/Oncology of Children's Hospital of Pittsburgh, Associate Professor of Pediatrics, University of Pittsburgh School of Medicine. In their discussion Dr. McAllister-Lucas talks about her research on MALT1 Lymphoma and how this research could advance the field of oncology 


Tags: cancer risk · cancer · children · pediatric cancer · childhood cancer · drug development · research · brain tumor · Advancement in Cancer Research

TWIPO #31 ~ Secondary Cancers in Childhood Cancer Survivors

February 10th, 2014 · Comments

October 03, 2013

Dr. Joseph Neglia (University of Minnesota) is nationally and internationally recognized for his contributions to the field of childhood cancer long-term effects. He is the featured guest in this week's podcast episode, and answers questions from host Dr. Tim Cripe (Nationwide Children’s Hospital), and co-hosts Dr. Robyn Dennis (Nationwide Children’s Hospital), Dr. Andy Kolb (AI DuPont), and Donna Ludwinski (Solving Kids’ Cancer), about late effects and the risk of secondary cancers among childhood cancer survivors.


Tags: families · cancer risk · children · childhood cancer · late effects

TWIPO #30 ~ Cancer Risk in Families

February 10th, 2014 · Comments

September 19, 2013

Recently, several published papers have discussed the risk of cancer among family members of children with cancer. TWIPO host Dr. Timothy Cripe and fellow co-host Dr. Robyn Dennis (Nationwide Children's) break down the topic of familial cancer risk with certified genetic counselor Elizabeth Varga (Nationwide Children's) and Donna Ludwinski (Solving Kids' Cancer) and what families should take away from these studies.


Tags: cancer risk · childhood cancer · Genetic counseling · funding

TWiPO #15 ~ MicroRNAs and hereditary cancer

February 10th, 2014 · Comments

September 28, 2011

Join host Dr. Tim Cripe with his co-hosts Drs. Jim Geller, Lionel Chow, and Lars Wagner in a robust discussion with special guest Dr. Kathryn Wikenheiser-Brokamp on the implications of DICER1, rare tumor registries, and difficult issues surrounding genetic counseling.

Kathryn A. Wikenheiser-Brokamp, MD, PhD, is an Associate Professor in Pathology and Pulmonary Biology at Cincinnati Children's Hospital Medical Center. Her research is focused on pediatric and adult lung diseases, including cancer. She seeks to determine the molecular mechanisms underlying Rb/p16, p53, and Dicer1 pathway function in lung development and the pathogenesis of lung disease. Dr. Wikenheiser-Brokamp holds a PhD in Developmental Biology, Developmental Biology and an MD from University of Cincinnati.

Papers discussed:

DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet. 2011 Apr;48(4):273-8.

Extending the Phenotypes Associated with DICER1 Mutations. Hum Mutat. 2011 Aug 31. doi: 10.1002/humu.21600.

Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. Gynecol Oncol. 2011 Aug;122(2):246-50.

Please send questions or comments to


Tags: cancer risk · children · childhood cancer · Genetic counseling

TWiPO #7 ~ Interview with E. Anders Kolb and Andrew Napper on drug development

February 10th, 2014 · Comments

June 02, 2011

In this seventh episode of "This Week in Pediatric Oncology" TWiPO podcast, host Dr. Tim Cripe interviews Dr. E. Anders Kolb and Dr. Andrew Napper  from Nemours in Wilmington, Delaware.

This informative discussion covers the strategies, scope, and challenges of target discovery, drug development, and preclinical testing for pediatric cancers, a complex process that has been accelerated by high throughput screening technology that has only recently become available in academic settings.

Dr. Kolb is the Director of Blood and Bone Marrow Transplantation at Alfred I. duPont Hospital for Children, and Head of the Cancer Therapeutics Laboratory at Nemours Biomedical Research. He is also a Principal Investigator in the Pediatric Preclinical Testing Program (PPTP), a comprehensive program to systematically evaluate new agents against childhood solid tumor and leukemia models.

Dr. Andrew Napper joined the research team at the Nemours Center for Childhood Cancer Research (NCCCR) in 2009 to establish its High Throughput Screening and Drug Discovery Laboratory. Dr. Napper came to Nemours from the University of Pennsylvania, where he was the Director of High Throughput Screening for the Penn Center for Molecular Discovery, one of the original ten centers established as part of the National Institutes of Health’s Roadmap initiative to discover drugs for neglected diseases.

For more information on this program and technology:

Lab Offer Hope for Kids with Cancer, Wilmington News Journal (8/24/09)

Academic screening goes high-throughput, Nature Methods 7, 787–792 (2010)

Please send questions and comments to


Tags: cancer risk · childhood cancer